EGFR and adenocarcinoma: It has also been shown that serum level of SP-D reflects its levels in the lung and that higher amount of SP-D in the serum correlated with better overall survival in patients with EGFR mutant adenocarcinoma undergoing treatment with gefitinib, a tyrosine kinase inhibitor (29).